IBC-0966

N/A

Report date: 2026/01/13 17:05:10

Base Information

Drug NameIBC-0966
Drug Alias NameIBC-0966
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionAnti-Programmed death-ligand 1Anti-Signal-regulatory protein alpha
TargetsProgrammed death-ligand 1Signal-regulatory protein alpha
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSunHo (China) BioPharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A